Biophan CEO Discusses Company’s Proprietary Technology in Online Interview with Smallcap Insights

LOS ANGELES–(BUSINESS WIRE)–March 11, 2005–Smallcap Insights, www.SmallcapInsights.com, the online source for exclusive commentary, research, interviews and other key investor information, has announced the availability of an audio interview given by Michael Weiner, CEO of Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology.

In the audio interview, Mr. Weiner provides an overview of Biophan’s proprietary intellectual property portfolio and products. The Company is an innovator in a range of biomedical technology, including solutions to make medical devices such as pacemakers safe and imageable under magnetic resonance imaging (MRI) systems. Other Biophan initiatives discussed in the interview are the company’s SQUIGGLE(TM) ceramic motor, advanced nanomagnetic coatings and drug delivery systems.

Mr. Weiner also discusses recent acquisitions and creation of the new Biophan-Europe division, as well as potential marketplaces for the Biophan solutions and future developments. The streaming audio interview can be accessed at http://www.SmallcapInsights.com. Registration to listen to the interview is free.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 108 U.S. patents, licenses or applications. This total includes 32 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA’s Ames Center for Nanotechnology. Biophan’s goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

About Smallcap Insights

Smallcap Insights provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. Smallcap Insights strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on SmallcapInsights.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at www.SmallcapInsights.com.

Forward-Looking Statements

Statements made on Smallcap Insights may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in — or suggested by — statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by Smallcap Insights.

Compensation and Other Disclosures

Smallcap Insights is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by Smallcap Insights are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from Biophan of $12,500 per month through February 2005 and thereafter for so long as Trilogy is retained to provide investor relations services. A subsidiary of Trilogy has entered into an agreement with a non-affiliate shareholder of this company pursuant to which the subsidiary has agreed to purchase from time to time from the third party under certain conditions up to an aggregate of 6,380,000 shares of common stock of this company at prices ranging from $.60 to $2.00 per share.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.